You searched for "AMM"

1865 results found

A phase 3 randomised trial of nicotinamide for skin cancer chemoprevention

To B3, or not to B3? That was the question asked in this controlled trial in which the authors were able to show that oral nicotinamide (vitamin B3) is able to reduce further skin cancer development in high risk patients....

Uveal melanoma

Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...

The focus group

I love conferences. Euretina I love above all others, and when it came to London in 2014 I was determined to attend. A few weeks before the conference was scheduled to begin a well-known pharmaceutical company sent me an email...

Data update for leading causes of CVI in England and Wales

In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...

Systemic pharmacology of intravitreal anti-VEGF

This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...

PRN Ranibizumab verses continuous aflibercept in UK clinical practice

This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Exploring the potential of neurodegenerative disease screening within age-related eye disease research

The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...

Lateral canthal position after lateral orbitotomy

This is a retrospective photographic study of changes in the lateral canthal position following a lateral orbitotomy performed via a lateral canthotomy and cantholysis of both upper and lower limbs of the lateral canthal tendon. Reconstruction of the lateral canthus...

The dynamic nature of orbital cavernous haemangiomas

This paper seeks to address the question of how much do orbital cavernous haemangiomas actually change over time, and if there are any identifiable factors which can predict which lesions will grow and which will remain stable. In particular, if...

Outcomes and complications of supramaximal levator resection

This is a report of 35 children with unilateral congenital ptosis who underwent a supramaximal levator resection, involving extensive dissection of levator including cutting Whitnall’s ligament. The average preoperative margin reflex distance to the upper lid (MRD1) was 0.5mm, and...

Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience

Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...